Find My Journal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, Ann‐Lii Cheng

The Lancet, 2018

Kindai University, 81th Hospital of PLA, Severance Hospital, Yonsei University, Toranomon Hospital, University of Bologna, California Pacific Medical Center, National Cancer Center, Air Force Medical University, Xijing Hospital, Gdańsk Medical University, Université de Bordeaux, Medizinische Hochschule Hannover, Russian Cancer Research Center NN Blokhin, University of Glasgow, Beatson West of Scotland Cancer Centre, Marqués de Valdecilla University Hospital, Eisai (United States), Eisai (United Kingdom), National Taiwan University Hospital

View Free PDF Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

5330

Citations

View on Google Scholar